Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trudemnrk Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO	Complete if Known		
INFORMATION DISCLOSURE	Application Number	10/625,307	
STATEMENT BY APPLICANT	Filing Date	July 23, 2003	
	First Named Inventor	Julia Elizabeth Thompson	
	Group Art Unit	1644	
(use as many sheets as necessary)	Examiner Name	Phillip Gambel	
Sheet 2 13	Attorney Docket Number	05569.0007.CPUS02	

				Foundation	
Ry	B8 -	WO 90/14430	11-29-1990	Scripps Clinic & Rescarch	
10				Foundation	
1	B9	WO 90/14443	11-29-1990	Huse	
	B10	WO 91/10737	07-25-1991	Molecular Affinities Corp.	
	BII	WO 91/17271	11-14-1991	Affymax Technologies, N.V.	
	B12	WO 92/06204	04-16-1992	lxsys, Inc.	
	B13	WO 92/09690	06-11-1992	Genentech, Inc.	
	B14	WO 92/18619	10-29-1992	Scripps Research Institute	
	B15	EP 0 368 684	03-09-1994	Medical Research Council	
	B16	EP A 0120694	10-03-1984	Celltech Limited	
	B17	EP A 0125023	11-14-1984	Genentech, Inc. et al.	
	B18	EP A 184187	06-11-1986	Teijin Limited	
	B19	EP A 0239400	09-30-1987	Winter	
	B20	EP B 0239400	09-30-1987	Winter	
	B21	GB 2188638	10-07-1987	Winter	
	B22	WO 91/04748	04-18-1991	La Jolla Cancer Research	l i
- 1	1			Foundation	
	B23	WO 92/01047	01-23-1992	Cambridge Antibody	
				Technology Ltd et al.	
í	1324	WO 92/17206	10-15-1992	The Victoria University of	
	_			Manchester	
	B25	WO 92/20791	11-26-1992	Cambridge Antibody	
				Technology Ltd ct al.	
	B26	WO 93/06213	04-01-1993	Medical Research Council et al.	
	1327	WO 93/11161	06-10-1993	Enzon, Inc.	
	B28	WO 93/11236	06-10-1993	Medical Research Council et al.	
- 1	1329	WO 93/14782	08-05-1993	La Jolla Cancer Research	- 1
L_				Foundation	
	B30	WO 93/17708	09-16-1993	Reed	
- 1	B31	WO 93/19783	10-14-1993	The Whittier Institute for	1
	B32	WO 93/21945	11-11-1993	Diabetes and Endocrinology The Regents of the Univ. of Cal	-+
- (1332	WC) 43/21945	11-11-1993	ct al.	. 1
	B33	WO 94/13804	-06-11-1992	Cambridge Antibody	—— -
ما	1	1.0 / 13804	4/1994	Technology Ltd. ct al.	1
-11-	1334	WO 94/18227	08-18-1994	Denzyme APS	

Examiner

| Between | Betw

Bruden Disug Statement: This form is estimated to take 2.0 bours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you care required to emprise this form inducts be sen to the Cher Information Officer. U.S. Patern tall Tradyman Coffice. Weshington, DC 20231. ONOT SEND FIES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Platents, Washington, DC 20231. 11/20

conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place mark here if English language Translation is